share_log

ResMed Shares Are Trading Lower After Rival Eli Lilly Received Approval for Zepbound as an Obstructive Sleep Apnea Treatment for Obese Adults.

ResMed Shares Are Trading Lower After Rival Eli Lilly Received Approval for Zepbound as an Obstructive Sleep Apnea Treatment for Obese Adults.

瑞思邁的股票因競爭對手禮來獲得批准將Zepbound作爲肥胖成年人阻塞性睡眠呼吸暫停治療而下跌。
Benzinga ·  12/24 00:23

ResMed Shares Are Trading Lower After Rival Eli Lilly Received Approval for Zepbound as an Obstructive Sleep Apnea Treatment for Obese Adults.

瑞思邁的股票因競爭對手禮來獲得批准將Zepbound作爲肥胖成年人阻塞性睡眠呼吸暫停治療而下跌。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論